Skip Navigation

Brain Tumor Clinical Trials

Clinical trials help bring hope, advance treatments, and often improve prognosis. Trials can be especially helpful for patients who have had a tumor come back, and the tumor is known to be aggressive and not responsive to current treatments.

Clinical trials are scientific studies in which new treatments are tested in patients to determine if they are safe and effective. Johns Hopkins has a long history of collaboration between basic scientists and clinical scientists, who advance new ideas from the laboratory to patients. We believe that well-designed and carefully conducted research will lead us to the next major breakthrough in the treatment of patients with malignant brain tumors.

To qualify for a clinical trial, participants must meet carefully defined criteria. Please contact the study nurse for the trial you are interested in to see if you qualify and if there are open spots in the trial. You may also reach out to our study nurses if you are unsure which trial is right for you:

 

Trials for Patients Who've Been Diagnosed with a Brain Tumor for the First Time

Study of Immunotherapy with Standard Chemoradiation vs. Standard Chemoradiation in Patients with New Glioblastoma who Received Gliadel Wafers (NCT05083754, J21103)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Lawrence Kleinberg
Objective: To evaluate retifanlimab, an immunotherapy drug, in adults who have already received Gliadel wafers to treat glioblastoma multiforme.
Eligibility Criteria: Adults with glioblastoma (GBM) that received Gliadel at the time of surgery
More information on clinicaltrials.gov: NCT05083754

Study of Subventricular Zone (SVZ) Irradiation+TMZ in New Glioblastoma (IRB00031466, J1426)

Contact: Kristin Redmond, MD (410-614-1642 or kjanson3@jhmi.edu) or Jacqueline Quivers (202-243-2294, jquiver1@jhmi.edu for Sibley location)
Principal Investigator: Dr. Kristin Redmond
Objective: To see if an investigational method of giving radiation to adults with glioblastoma multiforme (GBM) can improve the local control and increase the time it may take for your brain cancer from coming back.
Eligibility Criteria: Adults with glioblastoma (GBM)
More information on clinicaltrials.gov: NCT02177578

Study of Radiotherapy with Temozololide vs Radiotherapy with PCV Chemotherapy Anaplastic Glioma or Low-Grade Glioma (NCTNA0577, NA_00093264)

Contact: Phase1 Clinical Trials (JHCTN@jhmi.edu) and Jeannette Smith (jsmith@jhmi.edu)
Principal Investigator: Dr. Matthias Holdhoff
Objective: To compare standard chemoradiation with radiotherapy followed by PCV chemotherapy [PCV chemotherapy consists of three drugs, Matulane (procarbazine), Lomustine (CCNU) and Oncovin (vincristine)] in of anaplastic glioma or low-grade glioma
Eligibility Criteria: Adults with Anaplastic Glioma or Low Grade Glioma with the 1p/19q co-deletion and IDH tumor markers
More information on clinicaltrials.gov: NCT00887146

Study of Optune® Device (TTFields) with radiation therapy and temozolomide for newly diagnosed glioblastoma (IRB00283089, J2144)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Lawrence Kleinberg
Objective: To determine whether using Optune® (a tumor-treating fields device) during radiation therapy in the treatment of newly-diagnosed glioblastoma multiforme (GBM) improves survival when compared to starting Optune® following the completion of radiation therapy.
Eligibility Criteria: Adults with newly diagnosed GBM who have undergone surgery or biopsy and are planning to receive radiation therapy (RT) with concomitant temozolomide (TMZ)
More information on clinicaltrials.gov: NCT04471844

Trials for Patients Whose Brain Tumor Returned After Treatment

Study of [177Lu]-NeoB advanced solid tumors (including brain) that overexpress GRPR (gastrin-releasing peptide receptor) (IRB00204950, J1924)

Contact: Avery Spitz, RN (443-253-3894 or aspitz2@jhmi.edu)
Principal Investigator: Lilja Solnes
Objective: To see if the investigational product (NeoB) can be used safely to help
diagnose and treat advanced solid tumors.
Eligibility Criteria: People with advanced solid tumors, including brain tumors
More information on clinicaltrials.gov: NCT03872778

Study of DCA (Dichloroacetate) in Glioblastoma Multiforme (J2189, IRB00300857)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principal Investigator: Stuart Grossman
Objective: To find out if a drug called DCA (sodium dichloroacetate) can change the chemical reactions that help make GBM tumors grow.
Eligibility Criteria: People with glioblastoma (GBM) that has recurred and are planning to have surgery.
More information on clinicaltrials.gov: NCT05120284

Study for patients with recurrent gliomas that have a BRAF mutation treated with drugs to inhibit those mutations (RAF and MEK inhibitors) (IRB00158788, J1801)

Contact: Dr. Karisa Schreck, M.D. (ksolt1@jhmi.edu)
Principal Investigator: Dr. Karisa Schreck
Objective: To understand the amount of four drugs (dabrafenib, trametinib, encorafenib, and binimetinib) that is able to enter brain tumors and how well the drugs are able to turn off a specific pathway in these tumors. The study will also look at how tumors lose sensitivity to this treatment. Bio-specimens (tissue, blood and cerebrospinal fluid) taken during surgery will help us assess these research questions.
Eligibility Criteria: People with primary brain tumors who are already taking one or more of these drugs, and who need a brain surgery are eligible for this study.
More information on clinicaltrials.gov: NCT03593993

Study of PF-07284890 (ARRY-461) in BRAF V600-Mutant Solid Tumors With and Without Brain Involvement (IRB00271164, J20130)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principal Investigator: Dr. Karisa Schreck
Objective: To learn about the safety and the effects of study drug PF-07284890 and to find the best dose for treating certain cancer(s) when it is given alone or with binimetinib.
Eligibility Criteria: Adults with high-grade tumors with BRAF-V600
More information on clinicaltrials.gov: NCT04543188

Observational Studies and Supportive Care

Unlike clinical trials, observational studies are designed to observe rather than treat. In an observational study, researchers may evaluate changes in symptoms, results or side effects of a treatment, or how well different diagnostic methods detect or monitor brain tumors. For example, researchers may ask observational study participants to undergo an imaging test, such as MRI or PET scan to learn about diagnosing brain tumors from imaging. Both patients with brain tumors and healthy volunteers can participate in observational studies.

Temporary Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Suspected Glioblastoma (IRB00327491, J2238)

Contact: Kelly Szajna, RN, BSN (410-502-4081 or kszajna1@jhmi.edu)
Principal Investigator: Dr. Chetan Bettegowda
Objective: To test a new procedure to disrupt the blood brain barrier (Exablate BBBD with MRgFUS, or MR-guided focused ultrasound) and see what effects (good and bad) it has on the biomarkers released into the bloodstream.
Eligibility Criteria: Adults scheduled for brain tumor surgery

An MRI study for patients receiving high-dose methotrexate (IRB00237563, J2029)

Contact: Michaella Iacoboni, RN (410-955-4009 or msheeh13@jhmi.edu)
Principal and Co-Investigator: Dr. David Kamson and Dr. Stuart Grossman
Objective: To assess the feasibility to non-invasively detect and quantify chemotherapy drug concentrations using an MRI.
Eligibility Criteria: Patients with tumors already being treated with high-dose methotrexate chemotherapy

Protein and metabolite mapping of human muscle and brain by MRI (IRB00283785)

Contact: Contact: Jiadi Xu (410-598-0920 or jxu37@jh.edu)
Principal Investigator: Jiadi Xu
Objective: To examine the protein profile and metabolites changes after the chemotherapy using a non-invasive MRI method.
Eligibility Criteria: Healthy volunteers ages 18-80
More information on clinicaltrials.gov: NCT04234880

Human brain protein MR imaging and spectroscopy (NA_00034512, J0578)

Contact: Lindsay Blair (lblair1@jhmi.edu)
Principal and Co-Investigator: Jinyuan Zhou / Shanshan Jiang
Objective: To develop and refine a novel protein-based MRI technique, called amide proton transfer (APT) imaging, to better assess the status of disease in patients with brain tumors.
Eligibility Criteria: Known or suspected primary malignant brain tumors and healthy volunteers

Resource for quantitative functional MRI (IRB00036313)

Contact: Georg Oeltzschner (goeltzs1@jhmi.edu) and Lindsay Blair (lblair1@jhmi.edu)
Principal and Co-Investigator: Georg Oeltzschner
Objective: To develop and evaluate advanced spectral-edited magnetic resonance spectroscopic biomarkers of IDH and 1p/19q codelection in brain tumors

Development and translation of D-glucose as a diagnostic agent for MRI of cancer (NA_00049677)

Contact: Nirbhay Yadav (nyadav@jhu.edu) or Lindsay Blair (lblair1@jhmi.edu)
Principal and Co-Investigator: Peter van Zijl / Nirbhay Yadav
Objective: To develop and translate to the clinic the use of D-glucose as an intravenous MRI contrast agent for the combined imaging of tumor perfusion, permeability, and metabolism.
Eligibility Criteria: Brain mass consistent with a primary brain tumor or metastatic brain tumor and healthy volunteers

Browse other clinical trials

For a complete list of open clinical trials across Johns Hopkins, visit the database at the Institute for Clinical and Translational Research. You can search by condition, researcher or doctor’s name.

back to top button